[go: up one dir, main page]

MX2012012328A - Compuestos pirazol como inhibidores de jak. - Google Patents

Compuestos pirazol como inhibidores de jak.

Info

Publication number
MX2012012328A
MX2012012328A MX2012012328A MX2012012328A MX2012012328A MX 2012012328 A MX2012012328 A MX 2012012328A MX 2012012328 A MX2012012328 A MX 2012012328A MX 2012012328 A MX2012012328 A MX 2012012328A MX 2012012328 A MX2012012328 A MX 2012012328A
Authority
MX
Mexico
Prior art keywords
sup
compounds
jak inhibitors
pyrazole compounds
relates
Prior art date
Application number
MX2012012328A
Other languages
English (en)
Inventor
Richard John Harrison
Sally Oxenford
Andrew Hobson
Nigel Ramsden
Warren Miller
Original Assignee
Cellzome Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellzome Ltd filed Critical Cellzome Ltd
Publication of MX2012012328A publication Critical patent/MX2012012328A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La presente invención se refiere a los compuestos que tienen la fórmula (I), (Ver Formula) en la cual R1, R2, R1a, R1b, tienen el significado que se menciona en la descripción y las reivindicaciones. Tales compuestos son útiles como inhibidores de JAK para el tratamiento o profilaxis de enfermedades inmunológicas, inflamatorias, autoinmunes, alérgicas y enfermedades en las que interviene el sistema inmunológico. La invención también se refiere a las composiciones farmacéuticas que contienen estos compuestos, la preparación de los compuestos así como el uso como medicamentos.
MX2012012328A 2010-04-30 2011-04-18 Compuestos pirazol como inhibidores de jak. MX2012012328A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10161632 2010-04-30
PCT/EP2011/056158 WO2011134831A1 (en) 2010-04-30 2011-04-18 Pyrazole compounds as jak inhibitors

Publications (1)

Publication Number Publication Date
MX2012012328A true MX2012012328A (es) 2013-05-06

Family

ID=42711762

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012012328A MX2012012328A (es) 2010-04-30 2011-04-18 Compuestos pirazol como inhibidores de jak.

Country Status (12)

Country Link
US (1) US20130131043A1 (es)
EP (1) EP2566867A1 (es)
JP (1) JP2013525392A (es)
KR (1) KR20130094693A (es)
CN (1) CN103180322A (es)
BR (1) BR112012027803A2 (es)
CA (1) CA2797772A1 (es)
EA (1) EA201291038A1 (es)
MX (1) MX2012012328A (es)
SG (1) SG184989A1 (es)
WO (1) WO2011134831A1 (es)
ZA (1) ZA201208125B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110828A1 (es) 2008-10-31 2011-11-22 Genentech Inc Compuestos de pirazolopirimidina como inhibidores de jak
UA110324C2 (en) 2009-07-02 2015-12-25 Genentech Inc Jak inhibitory compounds based on pyrazolo pyrimidine
BR112013006016A2 (pt) 2010-09-15 2016-06-07 Hoffmann La Roche compostos de azabenzotiazol, composições e métodos de uso
BR112013011520A2 (pt) 2010-11-19 2019-09-24 Hoffmann La Roche pirazolo piridinas e pirazolo piridinas e seu uso como inibidores de tyk2
CN104169272A (zh) 2011-12-23 2014-11-26 赛尔佐姆有限公司 作为激酶抑制剂的嘧啶-2,4-二胺衍生物
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
AU2015261812B2 (en) 2014-05-23 2019-11-21 F. Hoffmann-La Roche Ag 5-chloro-2-difluoromethoxyphenyl pyrazolopyrimidine compounds which are JAK inhibitors
JP7256757B2 (ja) 2017-05-22 2023-04-12 エフ． ホフマン－ラ ロシュ アーゲー 処置用化合物及び組成物、並びにその使用方法
CN111433208B (zh) * 2017-12-05 2023-06-30 奥斯考泰克公司 作为lrrk2抑制剂的吡咯并(吡唑并)嘧啶衍生物
CN110446713B (zh) * 2018-06-06 2022-05-24 杭州澳津生物医药技术有限公司 一种吡唑嘧啶衍生物及其用途和药物组合物
CN110885331B (zh) * 2018-09-11 2021-07-09 中国药科大学 一种6-氨基-1H-吡唑并[3，4-d]嘧啶类JAK激酶抑制剂的制备与应用
WO2020092015A1 (en) 2018-11-02 2020-05-07 University Of Rochester Therapeutic mitigation of epithelial infection
US11136329B2 (en) * 2019-05-08 2021-10-05 Vimalan Biosciences, Inc. JAK inhibitors
TWI899080B (zh) * 2019-05-27 2025-10-01 大陸商迪哲（江蘇）醫藥股份有限公司 Ｄｎａ依賴性蛋白激酶抑制劑
TW202122400A (zh) * 2019-08-08 2021-06-16 美商維瑪蘭生物科學公司 Jak抑制劑
WO2021062036A1 (en) * 2019-09-25 2021-04-01 Vimalan Biosciences, Inc. Jak inhibitors
CN114901659A (zh) 2019-11-26 2022-08-12 施万生物制药研发Ip有限责任公司 作为jak抑制剂的稠合嘧啶吡啶酮化合物
WO2023107705A1 (en) 2021-12-10 2023-06-15 Incyte Corporation Bicyclic amines as cdk12 inhibitors

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6111298A (en) 1997-02-12 1998-09-08 Samir M. Hanash Protein markers for lung cancer and use thereof
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
TR200500745T2 (tr) 1999-02-10 2005-05-23 Astrazeneca Ab Damar gelişimi inhibitörleri olarak kuinazolin türevleri.
PL203782B1 (pl) 1999-11-05 2009-11-30 Astrazeneca Ab Pochodne chinazoliny,sposoby ich wytwarzania,ich kompozycje farmaceutyczne oraz ich zastosowania
PT1382339E (pt) 1999-12-10 2008-02-06 Pfizer Prod Inc Composições que contêm derivados de pirrolo[2,3-d]- pirimidina
SK287142B6 (sk) 2000-02-15 2010-01-07 Sugen, Inc. Inhibítory proteínkináz na báze pyrolom substituovaného 2-indolinónu, farmaceutický prípravok s ich obsahom a ich použitie
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
MXPA06007640A (es) * 2004-01-12 2007-04-17 Cytopia Res Pty Ltd Inhibidores de quinasa selectivos.
ZA200607981B (en) * 2004-03-30 2008-06-25 Vertex Pharma Azaindoles useful as inhibitors of jak and other protein kinases
AU2006205851A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
AU2006259153B2 (en) 2005-06-14 2012-04-12 Cellzome Gmbh Process for the identification of novel enzyme interacting compounds
EP1931675B1 (en) * 2005-10-06 2015-01-14 Merck Sharp & Dohme Corp. Pyrazolo(1, 5a) pyrimidines as protein kinase inhibitors
GB0605691D0 (en) 2006-03-21 2006-05-03 Novartis Ag Organic Compounds
EP1862802B1 (en) 2006-06-01 2008-12-10 Cellzome Ag Methods for the identification of ZAP-70 interacting molecules and for the purification of ZAP-70
RU2009105826A (ru) 2006-07-21 2010-08-27 Новартис АГ (CH) 2,4-ди(ариламино)питимидин-5-карбоксамидные соединения в качестве ингибиторов jak-киназ
WO2008060301A1 (en) 2006-11-16 2008-05-22 Pharmacopeia , Llc 7-substituted purine derivatives for immunosuppression
EP2108020A2 (en) * 2007-01-30 2009-10-14 Biogen Idec MA, Inc. 1-h-pyrazolo[3,4b]pyrimidine derivatives and their use as modulators of mitotic kinases
US7947698B2 (en) 2007-03-23 2011-05-24 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
WO2008118823A2 (en) 2007-03-26 2008-10-02 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
JP2010532756A (ja) 2007-07-06 2010-10-14 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド ｍＴＯＲＣ１及びｍＴＯＲＣ２の両方の阻害剤を含む組み合わせ抗癌療法
NZ587271A (en) 2008-02-06 2012-03-30 Novartis Ag Pyrrolo[2,3-d]pyrimidines containing a 7h-pyrrolo[2,3-d]pyrimidin-2-yl core and use thereof as tyrosine kinase inhibitors
CL2009001884A1 (es) 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
US20120040955A1 (en) 2009-04-14 2012-02-16 Richard John Harrison Fluoro substituted pyrimidine compounds as jak3 inhibitors
CA2771675A1 (en) 2009-09-11 2011-03-17 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors

Also Published As

Publication number Publication date
EP2566867A1 (en) 2013-03-13
WO2011134831A1 (en) 2011-11-03
SG184989A1 (en) 2012-11-29
CN103180322A (zh) 2013-06-26
US20130131043A1 (en) 2013-05-23
JP2013525392A (ja) 2013-06-20
KR20130094693A (ko) 2013-08-26
EA201291038A1 (ru) 2013-05-30
CA2797772A1 (en) 2011-11-03
ZA201208125B (en) 2013-08-28
BR112012027803A2 (pt) 2016-08-09

Similar Documents

Publication Publication Date Title
MX2012012328A (es) Compuestos pirazol como inhibidores de jak.
MX2012004020A (es) Analogos de heterociclilo pirazolopirimidina como inhibidores de jak.
WO2010142766A3 (en) Pyrimidine derivatives as zap-70 inhibitors
MX2013001929A (es) Nuevos compuestos
WO2012022681A3 (en) Heterocyclyl pyrazolopyrimidine analogues as selective jak inhibitors
UA102828C2 (en) Amino triazoles as p13k inhibitors
WO2009080638A3 (en) Sulfamides as zap-70 inhibitors
PH12018502125A1 (en) Bipyrazole derivatives as jak inhibitors
MX2009002171A (es) Derivados de triazol como inhibidores de cinasas.
UA99524C2 (ru) Триазолопроизводные, полезные для лечения болезней
PH12014502524A1 (en) Carboxylic acid compounds
IN2014DN09352A (es)
IN2014DN09348A (es)
CA2818187C (en) Bromodomain inhibitors and uses thereof
NZ708593A (en) Novel pyrazole derivative
EA201490357A1 (ru) Индазолы
PH12013501175A1 (en) 6-amino-2-phenylamino-1h-benzimidazole-5-carboxamide- derivatives and their use as microsomal prostaglandin e2 synthase-1 inhibitors
IN2014KN01075A (es)
MX367623B (es) 6-amino-nicotinamidas sustituidas como moduladores de kcnq2/3.
MX2013004759A (es) Compuestos de oxima como agentes de elevacion de colesterol de lipoproteina de alta densidad (hdl).
WO2013061004A8 (fr) Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines
PH12014502364A1 (en) Substituted pyrazole compounds as lpar antagonists
MX2011012669A (es) Nuevos agonistas del receptor de glucocorticoides.
IN2013DN02555A (es)
IN2014KN00849A (es)